Pharmaceutical Companies

The Alabama site is part of Lilly’s USD 27 billion U.S. onshoring initiative, aimed at reinforcing domestic pharmaceutical manufacturing.

YaoPharma stands to earn as much as USD1.94 billion in additional milestone payments tied to development, regulatory, and commercial achievements.

AGC Biologics now offers the ATUM transposase-based platform as part of its growing portfolio of cell line development solutions.

The two pharmaceutical giants originally signed the agreement in October 2025, establishing a framework centered on bispecific antibodies and ADCs.

The therapy delivers the full-length human frataxin gene using a dual-administration approach that combines direct intradentate nucleus (IDN) injection with intravenous (IV) infusion.

Itvisma works by delivering a functional copy of the survival motor neuron 1 (SMN1) gene through a single, fixed-dose intrathecal injection.

WT-7695, a preclinical radiopharmaceutical targeting carbonic anhydrase IX (CA9), was developed in collaboration with the University of Wisconsin-Madison, and SK now holds exclusive worldwide rights to develop, manufacture, and market the drug.

The project, supported by Tariq Almutlaq, Chairman of Daikin Saudi Arabia and a longtime partner, aims to localize production for key HVAC components, including chillers and hydronic heat pumps designed for sophisticated cooling requirements.

GEN1160 now joins GEN1107 on Genmab’s list of discontinued assets from the April 2024 ProfoundBio acquisition.

A company spokesperson explained that Moderna has “prioritized our pipeline and R&D investments as part of our broader cost efficiency efforts,” though the company provided no additional details about the specific discontinuations.